ZUMA-23: A Global, Phase 3, Randomized Controlled Study of A

Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.

Related Keywords

Jasonr Westin , , Randomized Controlled Study , Axicabtagene Ciloleucel Versus Standard Of Care , First Line Therapy , Patients With High Risk Largeb Cell , Zuma 23 , Zuma 23 Study , Axicabtagene Ciloleucel , Standard Of Care Largeb Cell Lymphoma , Largeb Cell Lymphoma , Lymphoma , High Risk Largeb Cell Lymphoma , First Line Treatments High Risk Largeb Cell Lymphoma , Zuma 7 , Zuma 1 , Zuma 12 , Axi Cel ,